PDF(Sci-hub)
Abstract：
BACKGROUND: A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/ml) (Bravecto® Plus) has been developed to provide broad spectrum parasite protection for cats. The effectiveness and safety of this product against ticks and fleas was assessed in a randomized, controlled, 12-week study in client-owned cats in Germany and Spain.
METHODS: Eligible households containing at least one cat with at least two fleas and/or two ticks were allocated randomly in a 2:1 ratio to a single treatment with fluralaner plus moxidectin on Day 0, or three 4-weekly treatments with fipronil (Frontline®). Veterinary staff, masked to treatment, completed tick and flea counts on each cat at 14 ± 2 (2 weeks), 28 ± 2 (4 weeks), 56 ± 2 (8 weeks) and 84 ± 2 days (12 weeks) after the initial treatment.
RESULTS: In total, 707 cats (257 with ticks) from 332 households (236 with fleas) were included. Ixodes ricinus (78%) and Rhipicephalus sanguineus complex (18%) ticks were the most commonly identified. Tick and flea counts were lower in the fluralaner plus moxidectin group than in the fipronil group throughout the study and the efficacy of fluralaner plus moxidectin exceeded 97 and 98%, respectively. At 12 weeks, 94.1 and 93.3% of cats from the fluralaner plus moxidectin and 92.2 and 60.3% of cats from the fipronil group were free of ticks and fleas, respectively. Fluralaner plus moxidectin was non-inferior to fipronil (P < 0.0001) at all assessments and superior to fipronil at 2 and 8 weeks for the proportion of cats free of ticks (P < 0.0001). Fluralaner plus moxidectin was superior to fipronil for the proportion of both households and cats free of fleas (P < 0.0001). Both products were safe and well tolerated.
CONCLUSIONS: A single application of fluralaner plus moxidectin spot-on was well tolerated by cats and highly effective for 12 weeks against ticks and fleas. Fluralaner plus moxidectin was non-inferior to fipronil for the proportion of ectoparasite-free and consistently superior to fipronil in controlling fleas.
METHODS: Eligible households containing at least one cat with at least two fleas and/or two ticks were allocated randomly in a 2:1 ratio to a single treatment with fluralaner plus moxidectin on Day 0, or three 4-weekly treatments with fipronil (Frontline®). Veterinary staff, masked to treatment, completed tick and flea counts on each cat at 14 ± 2 (2 weeks), 28 ± 2 (4 weeks), 56 ± 2 (8 weeks) and 84 ± 2 days (12 weeks) after the initial treatment.
RESULTS: In total, 707 cats (257 with ticks) from 332 households (236 with fleas) were included. Ixodes ricinus (78%) and Rhipicephalus sanguineus complex (18%) ticks were the most commonly identified. Tick and flea counts were lower in the fluralaner plus moxidectin group than in the fipronil group throughout the study and the efficacy of fluralaner plus moxidectin exceeded 97 and 98%, respectively. At 12 weeks, 94.1 and 93.3% of cats from the fluralaner plus moxidectin and 92.2 and 60.3% of cats from the fipronil group were free of ticks and fleas, respectively. Fluralaner plus moxidectin was non-inferior to fipronil (P < 0.0001) at all assessments and superior to fipronil at 2 and 8 weeks for the proportion of cats free of ticks (P < 0.0001). Fluralaner plus moxidectin was superior to fipronil for the proportion of both households and cats free of fleas (P < 0.0001). Both products were safe and well tolerated.
CONCLUSIONS: A single application of fluralaner plus moxidectin spot-on was well tolerated by cats and highly effective for 12 weeks against ticks and fleas. Fluralaner plus moxidectin was non-inferior to fipronil for the proportion of ectoparasite-free and consistently superior to fipronil in controlling fleas.
摘要：
背景:已经开发了含有fluralaner(280mg/ml)加莫昔克丁(14mg/ml)(Bravecto®Plus)的定点制剂来为猫提供广谱寄生虫保护。该产品对蜱和跳蚤的有效性和安全性进行了随机评估，控制,在德国和西班牙的客户拥有的猫中进行为期12周的研究。
方法:在第0天以2:1的比例随机分配含有至少一只具有至少两只跳蚤和/或两只蜱的猫的符合条件的家庭,在第0天用fluralaner加莫西克丁进行单次治疗,或者用氟虫腈(Frontline®)进行三次每周4次治疗。兽医人员,蒙面接受治疗，每只猫在14±2（2周）时完成蜱和跳蚤计数，28±2（4周），初始治疗后56±2（8周）和84±2天（12周）。
结果：总计，包括来自332户家庭（236家有跳蚤）的707只猫（257家有蜱）。最常见的是蓖麻（78％）和血根虫复合体（18％）。在整个研究过程中，fluralaner+moxidectin组的蜱和跳蚤计数低于fipronil组，fluralaner+moxidectin的疗效超过97％和98％，分别。12周时,来自fluralaner加moxidectin的猫中有94.1％和93.3％，来自fipronil组的猫中有92.2％和60.3％没有蜱和跳蚤，分别。在所有评估中，Fluralaner加moxidectin均不劣于氟虫腈（P<0.0001），在第2周和第8周时，无蜱猫的比例优于氟虫腈（P<0.0001）。Fluralaner加莫西丁在家庭和猫中无跳蚤的比例均优于氟虫腈（P<0.0001）。两种产品均安全且耐受性良好。
结论：猫对单一应用氟尿嘧啶加莫西克丁斑点具有良好的耐受性，并且对蜱和跳蚤有效12周。Fluralaner加moxidectin在无外寄生虫的比例方面不劣于氟虫腈，并且在控制跳蚤方面始终优于氟虫腈。
方法:在第0天以2:1的比例随机分配含有至少一只具有至少两只跳蚤和/或两只蜱的猫的符合条件的家庭,在第0天用fluralaner加莫西克丁进行单次治疗,或者用氟虫腈(Frontline®)进行三次每周4次治疗。兽医人员,蒙面接受治疗，每只猫在14±2（2周）时完成蜱和跳蚤计数，28±2（4周），初始治疗后56±2（8周）和84±2天（12周）。
结果：总计，包括来自332户家庭（236家有跳蚤）的707只猫（257家有蜱）。最常见的是蓖麻（78％）和血根虫复合体（18％）。在整个研究过程中，fluralaner+moxidectin组的蜱和跳蚤计数低于fipronil组，fluralaner+moxidectin的疗效超过97％和98％，分别。12周时,来自fluralaner加moxidectin的猫中有94.1％和93.3％，来自fipronil组的猫中有92.2％和60.3％没有蜱和跳蚤，分别。在所有评估中，Fluralaner加moxidectin均不劣于氟虫腈（P<0.0001），在第2周和第8周时，无蜱猫的比例优于氟虫腈（P<0.0001）。Fluralaner加莫西丁在家庭和猫中无跳蚤的比例均优于氟虫腈（P<0.0001）。两种产品均安全且耐受性良好。
结论：猫对单一应用氟尿嘧啶加莫西克丁斑点具有良好的耐受性，并且对蜱和跳蚤有效12周。Fluralaner加moxidectin在无外寄生虫的比例方面不劣于氟虫腈，并且在控制跳蚤方面始终优于氟虫腈。
